Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials?

This publication has 11 references indexed in Scilit:

• Abciximab Facilitates the Rate and Extent of Thrombolysis
  Circulation, 1999
• Relationship Between TIMI Frame Count and Clinical Outcomes After Thrombolytic Administration
  Circulation, 1999
• TNK–Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction
  Circulation, 1998
• TNK-Tissue Plasminogen Activator in Acute Myocardial Infarction
  Circulation, 1997
• Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 4 trial
  Journal of the American College of Cardiology, 1994
• The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial Infarction
  New England Journal of Medicine, 1993
• TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study.
  Circulation, 1993
• Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: Retrospective analysis of four german multicenter studies
  Journal of the American College of Cardiology, 1993
• Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study
  Journal of the American College of Cardiology, 1992
• DISCREPANCIES BETWEEN THE EFFECTS OF CORONARY REPERFUSION ON SURVIVAL AND LEFT VENTRICULAR FUNCTION
  The Lancet, 1989